It's no more elitist than an electrician telling someone that they can't wire their house themselves "because construction and safety organizations have studied this for decades and understand it more than you" when burning down the entire block is a very real possibility.
The consequences of breaches in medical ethics have been dire: to this day minority and aboriginal populations have worse health outcomes because they have lower trust in the medical establishment and even relatively small breaches in trust like the CIA vaccination program in Pakistan can have devastating effects like the revival of polio.
Bioethics and "modern" medicine are relative new so we're well into the conservative whiplash stage of the natural "boom and bust cycle" but for a damn good reason. You're not going to appreciate the seriousness of the subject without really digging into the very recent history of bioethics.
I do agree with OP that it's condescending to say that a non-PHD can't educate themselves enough for informed consent right now.
To me the time frame makes a difference though. Could one give informed consent in the first few months of a pandemic when we didn't know anything about the short and long term consequences? I think yeah it's their body they can jump in to benefit their family and all of us.
What about now that we have more data about immediate safety in younger adults and a bit more about potential longer term effects?
I agree with OP and don't think it's comparable to the serious problems you list.
Us non-scientists can understand enough to make this risk / society reward decision with our own bodies.
Can I consent to getting a taxi ride to the doctor's office, when we might get in a car crash and die?
The electrician isn't presenting themselves as an expert on the ethics of 240 volt plugs and which rooms you're allowed to install one in.
It's a big difference.
"The purpose of this study was to observe the natural history of untreated syphilis; the African-American men who participated in the study were TOLD that they were receiving free health care from the federal government of the United States."
Trust your government, Learn from the past.
Now is obviously all much better ?
FWIW, in general it is perfectly legal for a homeowner to do their own electrical work on their own home.
Experience alone is not enough. You must demonstrate evidence of actual expertise. Ethicists behave no more ethically than the average person[1], which strongly suggests that the entire field is worthless.
A rational person should ignore the established field of bioethics. Maybe even take the opposite of their advice.
[1]https://qz.com/1582149/ethicists-are-no-more-ethical-than-th...
I don't see how that follows. We don't expect our ethicists to behave more ethically any more than we expect our aeronautics engineers to fly.
We do generally expect a teacher to be able to explain a concept outside of their job, a writer to write a good note or letter, a photographer to take a good photograph when out casually with friends and family. Similarly we’d want people making moral judgement to demonstrate that capacity.
I don't understand why someone who studies ethics should behave better, any more than someone who studies the human musculature to be able to lift more weight.
Being less complicit in something that:
- causes immense, horrific suffering;
- has traditionally been, and still largely is, considered completely normal;
- requires some personal sacrifice to forego;
- happens because, and to the extent that, ordinary people continue to demand it
seems like a pretty big win to me, and a good argument that philosophical contemplation of ethical issues can be worthwhile.
(None of this implies that bioethics as a field is producing any value on net. Personally I'm unimpressed by what I've seen of it.)
If ethicists were more ethical than other humans, people here would be complaining that they are holier-than-thou and that they didn't represent the population's ethical wishes.
When a philosophy problem becomes well understood it tends to move into its own specialized field. For example the nascent fields of geometry, physics, and economics were all once part of philosophy. We get kind of a selection bias. Philosophers have a reputation for having their heads in the cloud, because we only think of the areas they've made the least progress in.
I otherwise wholeheartedly agree with everything you've written. Self-proclaimed expertise should be viewed with a very healthy scepticism, and the burden of proof isn't on you to show why they're wrong, it's on them to show why they're right without resorting to an argument from authority.
The reasons there are many outperformers are few fold.
Firstly, failing funds often close up shop and start anew, which artificially inflates the N success metric. The average number of hedge funds that a current manager has run is 2, since they've closed one failure on average.
Second, economic theory is a limiting condition, it's still remarkably easy to be lucky over a 5 year period given the low frequency nature of trades that many of these funds perform. It's not like a chronic gambler where the law of large numbers kicks in after two weeks.
Third, professional fund managers still do have edge over all other parts of the market (this has been shown in academic research), it's just that this edge is less than their fees, but it tilts the small sample statistics towards showing a large N successes compared to what we'd expect if they were trading randomly.
EMH and CAPM doesn't say that it's impossible to run an outperforming mutual fund over many years. All it says is that it's impossible to do so in expectation. Note that this is a statistical property pertaining to the law of large numbers. Nowhere in economic theory does it preclude a number of lucky outperformers, which is consistent with what we observe in reality (ie that there's a huge number of outperforming funds, and an even larger number of underperforming ones).
A finance professor would say "yes, there's hundreds of outperforming funds out there, likely some combination of luck and survivorship bias."
The efficient market hypothesis and the idea of efficient markets in general is not supported by evidence.
In a roulette game, each outcome is drawn from the same, well understood distribution, so we can easily calculate the probability that a sequence of outcomes is observed when the null hypothesis distribution applies.
In trading this is much harder, given the null hypothesis distribution is unknown and hard to estimate, and trades aren't i.i.d. since regimes come and go and therefore the luck of a specific style can be autocorrelated over a number of years. Trades are also correlated in the cross section through betas.
I'm going to go ahead and say that it's an impossible task if we're dealing with 10-20 year timeframes and the fund had a low frequency style. It's just way too easy to be lucky over a course of multiple years. All you really need is 1 lucky call combined with index tracking on the remaining capital to outperform ("overweight AMZN").
So you can't prove much about very passive investors.
But if someone is making a 2:1 payout decision every month, and manages to be right 75% of the time, you can be quite sure it's not luck.
If there aren't enough exploitable inefficiencies in an entire career to make that proof, then that's an interesting data point all on its own.
What you're requesting is that this happens in a specific way. That specific way might not be the way that is optimal.
Had the clinical trials run in a "less ethical" way, say by taking young and healthy people like myself, vaccinating them and then deliberately exposing them to COVID, then we might have seen vaccination start much sooner. Far fewer would have died and the colossal impact of lockdowns would have been mostly avoided.
I may have misremembered slightly but I seem to recall 42 days fromm sequence identification, leveraging a roughly 10-year project related to related coronavirus work (MERS).
So, not exactly a weekend.
Also, there were several candidates developed in parallel, but others failed at various trial stages. Less effective testing (and your proposal is less effective, both for safety and efficacy) might mean people get vaccines sooner, but it also means they get less effective and more dangerous vaccines sooner, meaning more people die of vaccines (bad for first order effects, and worse for the second order effect of increasing public vaccine reluctance) and that instead of stopping spread by vaccination we increase the selective pressure for diverse, resistant new variants without doing so.
And what exactly would that have told you about the safety and effectiveness of the vaccine for the people at risk, those who are neither young nor healthy?
And how many people would you need to challenge to show that the vaccine prevents deaths or even serious disease? The young and healthy rarely get the full brunt of the disease.
To your specific question, you still derisk it for the elderly. If it causes problems in young adults, you quit because it would probably cause even more problems in riskier groups. If it doesn't, you move forward into older groups.
Let's not pretend you would learn nothing that would speed things along. Some of these questions aren't answered quantitatively even now.
Of course. These are all great uses for challenge studies, I was responding specifically to testing the vaccine using a challenge study on healthy young adults.
> If it causes problems in young adults, you quit because it would probably cause even more problems in riskier groups. If it doesn't, you move forward into older groups.
It turns out that both Pfizer and Moderna trials have shown much more adverse reactions in the young than the old.
Testing on the wrong population may result in rejecting a vaccine that could be perfectly safe on the at-risk population, but inappropriate for the general population.
> Let's not pretend you would learn nothing that would speed things along
Of course not. You could learn a lot, just not about the safety and efficacy profile of the vaccine on the at-risk population.
So if the goal was to reduce transmission, you can save a lot of lives of those at risk by vaccinating the young and healthy. It would be reasonable to basically use challenge studies to get a lower transmission rate, while in parallel using standard trials to prove the efficacy in at risk populations.
Getting more data quicker is usually a good way to make more informed decisions, even if the data isn’t exactly what you want it to be to make the perfectly optimal choices.
Has this been tested yet? Is there evidence that this is true beyond the broad population surveys like those from Israel? (The accuracy of those data were hotly debated here last week.)
Surely a study to determine actual transmission rates would be much more complex than one to determine whether young & healthy people are infected after inoculation (which again: not that useful of a data point by itself)?
The Tetanus vaccine targets the toxin, not the pathogen.
Some research may indicate that the current a-cellular whooping cough vaccine prevents symptoms, but not transmission. The older vaccine prevented transmission, but had too many side effects.
The oral polio vaccine may actually result in outbreaks of the vaccine strain.
http://www.emro.who.int/syr/syria-news/polio-outbreak-succes...
Claims about prevention of transmission needs to be demonstrated in a trial, not simply asserted.
Supposedly, the Pandemrix fiasco happened because the antibodies generated by the vaccine cross reacted with some human proteins.
The lengthy drug approval regimen exists not because of some power drunk bureaucrats. It exists because of a long history of dangerous and ineffective drugs that looked really great in theory.
Likewise, it is not surprising that injecting a live polio virus can cause an infection. That is a different claim than saying a vaccinated person will get infected and transmit later once immune. Further, the coronavirus vaccines do not use live viruses.
Whooping cough is the example people love to bring up. I’ll paste in full my prior comment on this. The worst case example reduces transmission at least 30%! And probably more: it was completely sterilizing in 30% but may well have reduced transmissibility in other groups. And that’s the very worst case vaccine.
———————-
I looked into this, and it does seem the vaccine reduces transmission. It just doesn’t stop it entirely. The paper below is Wikipedia’s source. Upon a close read, in the daycare there were three groups of vaccinated children: * Those positive for antibodies but pcr negative —> had been exposed, cleared virus without infection * those pcr positive but asymptomatic * those pcr positive and symptomatic About 30% were in the seropositive group which didn’t have pcr positivity. So it seems like transmission was reduced at least 30%. It’s also possible the other two groups would have had lower transmission rates than if they had had no vaccine. If you have a more precise source I’d be interested to see it, but if this is the worst case it’s pretty good! > We used PCR, EIA, and culture to confirm B. pertussis infection in two highly vaccinated groups of children in two day-care centers. Three (10%) of 30 2- to 3-year-old children were seropositive for recent infection; one had nasopharyngeal colonization and a clinical illness that met the modified WHO case definition. In the day-care center for the 5- to 6- year-old group, 9 (55%) of 16 children were IgM positive, 4 (25%) of whom had nasopharyngeal colonization. Of these four children, three had nonspecific cough, and only one met the modified WHO definition for pertussis. None of the children in our study, including those who met the WHO definition, had been examined by a physician before our investigation. >Children who were seropositive and re- mained both asymptomatic and PCR negative probably had sufficient immunity from vaccines or natural boosters to protect them against persistent colonization and clinical disease. Their seropositivity could not be due to vaccine because the children were tested more than a year after having been vaccinated.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2627963/pdf/109...
There's no comparison between transmission by vaccinated and non-vaccinated children, so there's no possible way of concluding that vaccination reduced transmission relative to non-vaccination.
You would not expect to see seropositive but pcr negative students if unvaccinated.
- apparently high asymptomatic rate
- somewhat unpredictable who will get severe case
- random neurological symptoms in a respiratory virus
And most/all of the vaccines we are using will be the first approved for human use on their respective platforms. It's worth looking at.
Also, for a pathogen that is so highly transmissible, it's worth understanding what we mean by "reduced transmission". Is it 10% less? 90%? Surely this would be important to know before following a strategy of vaccinating the young and healthy first. (Especially given the difficulty of doing so in a population that is least likely to suffer serious harm from the pathogen.)
We vaccinated no one in that period as it is.
Given those assumptions, there still needs to be a smaller safety trial before a large challenge trial. BioNTech started those in April, that ended in May. Deployment in the summer is already aggressive, assuming no challenge trials and we had just deployed vaccines shown to be safe in very small trials.
But suppose a challenge trial was run rapidly over the next three months (to determine which of the BioNTech candidates was best). Assume this all goes optimally. This plan still assumes the existence of scale manufacturing facilities that likely did not exist last summer. Let's wish that away too, so we have scaled manufacturing capacities to June 2021 levels by May 2020. While we have our magic wand out, let's wave away the fact that the vaccine initially took over 100 days to manufacture, so that in our world we can decide what to produce today and have it ready tomorrow instead of next quarter. So we've got positive challenge trial results in July 2020 with faster-than-2021 production capacity to go to scale.
Now, perception-wise, we are asking young healthy people to take a vaccine designed on a novel platform that was rushed through a novel ethics-skirting approval process, for a virus that likely won't seriously harm them if they get it. I'm not sure that would be as effective as people seem to think it is.
It would have sped up subsequent production too.
You could take 50 people, vaccinate half and give half a placebo, infect them with Covid, then put them in 50 rooms with 50 other unvaccinated people (so each has two people) for 2 weeks and see what happens.
The reason you can’t do it without a challenge trial is exactly because of what you said - you can’t track infections in the community.
Also note that had this been run last spring you've doubled the size of the trial and therefore the number of hospitalized patients who would not have life-saving therapeutics. By comparison, the BioNTech/Pfizer vaccine had over 40,000 people in its trial. Not sure you could even run a trial that big with even a tenth as many people.
In a challenge trial you can make people cough in each other’s faces, or literally inject them with Covid depending on the study, which raises your chance of getting people infected and seeing the impact. You would expect the control group to have a very high infection rate, and to see the difference in the study group much more easily.
I’m not saying 100 people would be enough, but you would need significantly fewer people fewer to get a good level of confidence.
And again -- the backup therapeutics that enable any challenge trial were not broadly available until a month or two before vaccines went into wide deployment. (You will note that nobody is volunteering for a challenge trial for any drugs or vaccines for our other ongoing pandemic, HIV. Lack of backup therapeutics is a big reason for that.)
People were actually volunteering for a challenge trial for Covid prior to theraputics being available - because Covid actually is low-risk for the groups in the challenge trial (young people) and the vast majority of people recover. I don't think theraputics are necessary for a challenge trial, as long as there is sufficient benefit, the risk is sufficiently low, and volunteers are aware of the personal risks (aware this criteria is ambiguous!).
HIV is incurable, however there are excellent therapeutics. Despite this, the prognosis of HIV is much worse than someone with Covid.
And that's the bad outcome where the slower trials in more at risk people don't work out. In the good outcome, when you decide it is safe and effective in vulnerable people, production and administration have already been scaled out.
(could study viral load in a challenge trial where you don't have to test thousands of uninfected people to find asymptomatic cases…)
> The limiting factor in the speed of the clinical trials is the rate at which people acquire COVID naturally.
That's only one of the factors. It takes weeks to go from infection to disease outcome. If you're also interested in safety, you have to enroll tens of thousands of people, give them the vaccine, and wait to see if there are side-effects. And of course, you have to scale up production. In the grand scheme of things, the wait for people to get naturally infected in phase-3 trials was relatively short (a few weeks).
> Far fewer would have died and the colossal impact of lockdowns would have been mostly avoided.
Countries that had extremely strict lockdowns were able to reopen nearly completely with extremely low virus prevalence, and then to control the virus with good tracing. China has been mostly open since last spring, and fewer than 5000 people have died in total in the country (almost all of them in the first 3 months of the outbreak).
I count 4 months of phase 1/2 and 5 months of phase 3 (also note that there is some degree of confidence in the safety from the initial results of the phase 2 study).
I would think any challenge trial would be an additional study, not a replacement, a study that overlapped with phase 2 and 3 in information gathering (enrolling a smaller number of people but gathering more efficacy data per enrollee).
1 and 2: https://www.nih.gov/news-events/news-releases/experimental-c...
3: https://investors.modernatx.com/news-releases/news-release-d...
We can now tell that testing, up to now, results in over 2 million deaths. What would the risks have been for not testing?
Most of the CoVID-19 deaths around the world have been avoidable, even without a vaccine. Countries that reacted properly (mostly in East Asia and Oceania) have had orders of magnitude fewer deaths per capita. Rather than rushing out a vaccine before doing any safety or efficacy testing, I'd rather that countries had controlled the virus with non-pharmaceutical interventions early on.
We’ve got some vaccines that work, a few that don’t, and at least one candidate that looked promising but was abandoned for problematic side effects (false-positives on HIV tests).
You can’t just divide those out though, because all of this work was done in systems where people expected thorough testing. In a world where we didn’t test, the ”honest” attempts might not be as careful and there would also be a number of outright scams.
How does this not beat 2 million deaths?
Suppose we did and HIV tests start going off like fireworks a month later. Rumors start spreading about how it gives you AIDS, and uptake craters, probably for other vaccines as well. You’re right that this isn’t even the worst outcome. We also could have rolled out GSK’s failed candidates—-or one of Merck’s two. We’d be back where we started, but poorer, with less public support, and potentially dealing with widespread immunity to the vector. Solid preclinical candidates go sideways all the time, so it could have been even worse.
No argument whatsoever that 2MM deaths is awful and tragic. However, it’s the Slateist of Slate pitches to claim that “testing is the real killer.” We had plenty of easy ways to mitigate this (e.g., masks) but, for a variety of stupid reasons, chose not to use them.
Beats 2 million deaths.
And please, don’t give me the magical masks excuse. Masks might give additional protection, in no way do they solve the issue. And the ‘if only’ statements of some time ago have clearly been proven false. ‘If only we would have worn the masks corona would have been over’. No it wouldn’t because now it’s ‘if only we had worn three masks on top of each other’, which wouldn’t have been necessary if the first statement was true. It just isn’t. It’s easy blameshifting.
As for the rest, two words: New Zealand. Also Vietnam, Taiwan, Singapore, Atlantic Canada, and China (though you may not trust their numbers). A huge proportion of these deaths were avoidable.
I’m not even going to comment on the New Zealand utopia fantasy.
Having no knowledge of the field of ethicists, i would imagine that these are the kinds of things they debate all day long, theres a million variations on the same question.
On the face of it, this is an uninformed opionion, whether or not it was "created in weekend" or not.
On the face of it, I would call it the truth.
As to say, not very "created in a weekend."
Very much ‘created in a weekend.’
It’s a choice whether you do a year long three phase trial. Or not. The vaccine (recipe) still exists.
How would a challenge trial in health 20-30 year olds help when most of the people dying are over 70?
Do you just wave your hands and extrapolate?
[1] https://academic.oup.com/jid/article/221/11/1752/5814216 [2] https://pubmed.ncbi.nlm.nih.gov/33334616/ [3] https://pubmed.ncbi.nlm.nih.gov/32441894/ [4] https://foster.house.gov/hhs-fda
None of these points pertain to the scientific, medical or ethical rationales behind doing human challenge trials.
"46.107 IRB membership
(a) Each IRB shall have at least five members, with varying backgrounds to promote complete and adequate review of research activities commonly conducted by the institution. The IRB shall be sufficiently qualified through the experience and expertise of its members, and the diversity of the members, including consideration of race, gender, and cultural backgrounds and sensitivity to such issues as community attitudes, to promote respect for its advice and counsel in safeguarding the rights and welfare of human subjects. In addition to possessing the professional competence necessary to review specific research activities, the IRB shall be able to ascertain the acceptability of proposed research in terms of institutional commitments and regulations, applicable law, and standards of professional conduct and practice. The IRB shall therefore include persons knowledgeable in these areas. If an IRB regularly reviews research that involves a vulnerable category of subjects, such as children, prisoners, pregnant women, or handicapped or mentally disabled persons, consideration shall be given to the inclusion of one or more individuals who are knowledgeable about and experienced in working with these subjects.
(b) Every nondiscriminatory effort will be made to ensure that no IRB consists entirely of men or entirely of women, including the institution’s consideration of qualified persons of both sexes, so long as no selection is made to the IRB on the basis of gender. No IRB may consist entirely of members of one profession.
(c) Each IRB shall include at least one member whose primary concerns are in scientific areas and at least one member whose primary concerns are in nonscientific areas.
(d) Each IRB shall include at least one member who is not otherwise affiliated with the institution and who is not part of the immediate family of a person who is affiliated with the institution.
(e) No IRB may have a member participate in the IRB’s initial or continuing review of any project in which the member has a conflicting interest, except to provide information requested by the IRB.
(f) An IRB may, in its discretion, invite individuals with competence in special areas to assist in the review of issues which require expertise beyond or in addition to that available on the IRB. These individuals may not vote with the IRB."
[0] https://www.hhs.gov/ohrp/regulations-and-policy/regulations/...
How would it be better if they were elected?
only if the people aren't blinded by partisanship and realize it.
To the bioethicists, ok, boomer.
I found this extremely unconvincing. A group of unelected people, mostly from the same social class, being able to determine the rules of something so important seemed inherently flawed to me.
In this particular situation, I saw it as signing up to be a soldier for my country (which always covers some personal risk) - with the number of lives that could have been saved by April 2020 human challenge trial being in the tens or hundreds of thousands of dollars.